Nov
08
A Trial Is Testing Supplements the Way People Actually Take Them
0 Comments
Almost every supplement trial asks whether one compound beats a placebo in everybody. A protocol published in GeroScience does something closer to what people actually do: several compounds at once, assigned by what each participant measures low on, and changed when the measurements do not move.
The short version
PROMETHEUS is an eight-week study in 20 middle-aged to older participants, run as part of the XPRIZE Healthspan competition, where the team reached the semi-final. The protocol was published in GeroScience in 2026 by Anna Kuerec and colleagues.
Every participant gets a base layer: sleep and dietary guidance, supervised exercise including dual-task cognitive and physical training, motivational interviewing and cognitive behavioural therapy, plus whey protein, creatine and fucoidan.
On top of that sits the part worth reading twice. Each participant is measured at baseline on muscle mass, VO2peak and cognitive performance, sorted into what the authors call a gerotype, and prescribed accordingly. Depending on where they fall short, they receive urolithin A, nicotinamide mononucleotide, or a multivitamin-multimineral, or some combination.
Then at the midpoint the protocol does something trials almost never do. Participants are reassessed, and anyone whose results have not improved enough gets their dose escalated, or ergothioneine added for inadequate cognitive response. The intervention adapts to the person during the study rather than being fixed at the start.
What to do with that: copy the logic, not the list. Two habits here are worth adopting immediately and cost nothing. First, assign compounds against something you have actually measured rather than against a general wish to be healthier, which means knowing your own grip strength, your aerobic capacity and some cognitive baseline before deciding what to take. Second, set a date eight to twelve weeks out to re-measure, and treat an unchanged measurement as information. Most people never close that loop and so keep taking things indefinitely with no idea whether any of it is working.
Why the design is the news
The standard supplement trial takes one compound, splits a population in two, and reports an average. It is the right design for a regulator and a poor one for a person, because the average conceals the question that matters: did it work for people like me, and would it have worked better alongside something else.
It also mismatches reality. Nobody takes one thing. The population that buys longevity supplements takes several, alongside exercise and whatever they are doing about sleep, and a trial that isolates one variable is answering a question nobody is living.
PROMETHEUS accepts the mess instead of controlling it away. The cost is obvious and the authors are open about it: when you change several things at once you cannot attribute the result to any one of them. The gain is that the result, whatever it is, describes something a person could actually do.
What is in the protocol
The fundamental layer, given to everyone: sleep and dietary recommendations, whey protein, creatine, fucoidan, supervised exercise with an exergaming component that loads cognitive and physical demand at the same time, motivational interviewing and cognitive behavioural therapy.
Creatine and whey are the least glamorous things on that list and probably the best evidenced for preserving muscle with age. Fucoidan, a sulphated polysaccharide from brown seaweed, is the more speculative inclusion. Putting the behavioural work in the same layer as the compounds is a quiet statement about what the authors think actually drives adherence.
The augmented layer, assigned by baseline measurement:
- Urolithin A, produced in the gut from pomegranate ellagitannins by bacteria that only some people carry, which is why it is given directly. It acts on mitophagy, the clearing of damaged mitochondria.
- Nicotinamide mononucleotide, an NAD precursor, sitting upstream of the sirtuins.
- Multivitamin-multimineral, which is there to cover deficiency rather than to do anything clever.
- Ergothioneine, added at the midpoint for insufficient cognitive response. An amino acid derivative concentrated in mushrooms, taken up by a dedicated transporter, which is unusual and suggests the body means to keep it.
Primary outcomes are muscle strength and mass, immune function and cognitive performance, plus the feasibility measures any pilot needs: did people adhere, did they finish. Secondary outcomes include biological, clinical and digital aging biomarkers, and qualitative work on motivation and personal values (Kuerec et al., 2026).
The gerotype idea
The premise behind the personalisation is that people of the same chronological age are not aging along the same axis. One person’s limiting system is muscle, another’s is aerobic capacity, another’s is cognition. Giving all three the same capsule and averaging the result will understate what it did for the person whose deficit it addressed and overstate what it did for the other two.
This is not a new idea, but it is rarely operationalised. Here it decides who gets which compound.
Whether three baseline measures are enough to define a gerotype is a fair question and the authors are not claiming it is settled. It is a first pass at a problem the field has mostly handled by ignoring it.
What it cannot tell us
This is a protocol paper. There are no results, and when results arrive they will come from 20 people over eight weeks.
No control group is described for the multimodal intervention, which is appropriate for a feasibility study and means nothing in it will establish efficacy. Everything changes at once, so attribution is impossible by design. The stated purpose is to test recruitment, safety and adherence, and to shape the 12-month randomised trial that follows.
That follow-on trial is the one to watch. The authors say it may incorporate repurposed pharmaceutical agents alongside the lifestyle and nutraceutical arms, which would put compounds people can buy and drugs they cannot in the same comparison for once.
Why we find this encouraging
Our position has been that aging is multifactorial and support for it should be too, and that the single-compound trial is a format inherited from pharmacology that does not fit what nutraceuticals are for. The usual response is that multi-component interventions cannot be studied rigorously.
PROMETHEUS is a serious group, inside a serious competition, publishing a protocol in a respectable journal, designed around exactly that supposed impossibility. The design is imperfect and openly so. It is still a better map of the territory than one more placebo-controlled trial of one capsule.
Where this leads
If the feasibility results are good, the 12-month randomised trial becomes the most informative thing happening in this field for people who take supplements rather than write about them. We will cover it when it reports.
In the meantime our research database holds our work on the individual compounds in this protocol, and the multi-target guide sets out why combinations are the frame we work in.
Limitations
No results exist yet, the sample is 20 people over eight weeks with no control arm for the multimodal intervention, and the simultaneous changes mean nothing in it will be attributable to any single compound.
Citations
[1] Kuerec AH, Guan L, Wang W, Barros D, Alenezi WM, Grgic J, et al. PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals. GeroScience. 2026;48(5):6389-6407. doi:10.1007/s11357-026-02394-6. PMID 42393428
These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.
Categories:
Longevity in the News
